If you glance at a diagram of the continuum of translational research, the arrows point orderly to five phases — from basic research to improving population health.
Pediatric cancer researchers at The Children’s Hospital of Philadelphia believe they have succeeded in their search for a powerful next-generation drug for neuroblastoma tumors with mutations in the anaplastic lymphoma kinase (ALK) gene associated with the cancer.
